Pantoprazole sodium hydrate (BY1023 sodium hydrate; 1-10000 μM) leads to concentration-dependent increases in endosomal pH in EMT-6 and MCF7 cells. Pantoprazole sodium hydrate can block exosome release. Pantoprazole sodium hydrate inhibits the activity of V-H + -ATPase and impaires the ability of tumour cells (melanomas, adenocarcinomas, and lymphoma cell lines) to acidify the extracellular medium
Pantoprazole sodium hydrate (BY1023 sodium hydrate; 200 mg/kg; IP; once a week for 3 weeks) significantly increases tumor growth delay of MCF-7 xenografts combined with Doxorubicin. Pantoprazole sodium hydrate (0.3-3 mg/kg, p.o.) dose-dependently decreases both basal acid secretion in pylorus-ligated rats and the stimulated acid secretion induced by mepirizole in acute fistula rats.